The blood–brain barrier and blood–tumour barrier in brain tumours and metastases
For a blood-borne cancer therapeutic agent to be effective, it must cross the blood vessel
wall to reach cancer cells in adequate quantities, and it must overcome the resistance …
wall to reach cancer cells in adequate quantities, and it must overcome the resistance …
The blood–tumour barrier in cancer biology and therapy
PS Steeg - Nature Reviews Clinical Oncology, 2021 - nature.com
The protective blood–brain barrier has a major role in ensuring normal brain function by
severely limiting and tightly controlling the ingress of substances into the brain from the …
severely limiting and tightly controlling the ingress of substances into the brain from the …
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
Trastuzumab deruxtecan is an antibody–drug conjugate with high extracranial activity in
human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. We …
human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. We …
Fatty acid synthesis is required for breast cancer brain metastasis
Brain metastases are refractory to therapies that control systemic disease in patients with
human epidermal growth factor receptor 2-positive breast cancer and the brain …
human epidermal growth factor receptor 2-positive breast cancer and the brain …
Brain metastases
AS Achrol, RC Rennert, C Anders, R Soffietti… - Nature Reviews …, 2019 - nature.com
An estimated 20% of all patients with cancer will develop brain metastases, with the majority
of brain metastases occurring in those with lung, breast and colorectal cancers, melanoma …
of brain metastases occurring in those with lung, breast and colorectal cancers, melanoma …
Shortwave infrared fluorescence imaging with the clinically approved near-infrared dye indocyanine green
Fluorescence imaging is a method of real-time molecular tracking in vivo that has enabled
many clinical technologies. Imaging in the shortwave IR (SWIR; 1,000–2,000 nm) promises …
many clinical technologies. Imaging in the shortwave IR (SWIR; 1,000–2,000 nm) promises …
Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas
Immune checkpoint blockers (ICBs) have failed in all phase III glioblastoma (GBM) trials.
Here, we show that regulatory T (Treg) cells play a key role in GBM resistance to ICBs in …
Here, we show that regulatory T (Treg) cells play a key role in GBM resistance to ICBs in …
Trastuzumab deruxtecan in HER2-positive metastatic breast cancer patients with brain metastases: a DESTINY-Breast01 subgroup analysis
G Jerusalem, YH Park, T Yamashita, SA Hurvitz… - Cancer discovery, 2022 - AACR
Abstract DESTINY-Breast01 (NCT03248492) evaluated trastuzumab deruxtecan (T-DXd; DS-
8201) in patients with heavily pretreated HER2-positive metastatic breast cancer (mBC). We …
8201) in patients with heavily pretreated HER2-positive metastatic breast cancer (mBC). We …
Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood–tumor barrier disruption
Blood–brain/blood–tumor barriers (BBB and BTB) and interstitial transport may constitute
major obstacles to the transport of therapeutics in brain tumors. In this study, we examined …
major obstacles to the transport of therapeutics in brain tumors. In this study, we examined …
[HTML][HTML] Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from …
Background Patients with brain metastases (BM) from human epidermal growth factor
receptor 2 (HER2)-positive breast cancer represent a difficult-to-treat population …
receptor 2 (HER2)-positive breast cancer represent a difficult-to-treat population …